Open access · OA
via Europe PMC
Lysine Acetylation as a Regulatory Mechanism in Cardiometabolic Disease: A Focus on Sirtuins.
Pharmaceuticals (Basel, Switzerland) · 2026
Abstract
Protein lysine acetylation is a widespread post-translational modification that regulates metabolic enzyme activity and cellular function. Sirtuins (SIRTs) are a family of nicotinamide adenine dinucleotide (NAD<sup>+</sup>)-dependent deacetylases that act as key metabolic sensors coupling cellular energy status to the regulation of protein acetylation. Dysregulation of sirtuin activity, particularly sirtuin 1 (SIRT1) and sirtuin 3 (SIRT3), has been implicated in the pathogenesis of cardiometabolic diseases, including obesity, type 2 diabetes, cardiovascular disease and metabolic dysfunction-associated steatotic liver disease. Under conditions of nutrient excess, alterations in acetyl-coenzyme A (acetyl-CoA) and NAD<sup>+</sup> availability promote mitochondrial protein hyperacetylation, contributing to impaired mitochondrial respiration. Evidence from genetic and proteomic studies across metabolically active tissues such as the liver, heart, adipose tissue, skeletal muscle and pancreatic β-cells, highlight a central role for sirtuins in maintaining metabolic homeostasis. Therapeutic strategies aimed at improving mitochondrial function through activation of sirtuins have gained significant attention. Early studies focused on natural sirtuin activators, such as resveratrol and honokiol, while subsequent efforts led to the development of synthetic small-molecule activators, although their mechanisms of action remain debated. More recently, small molecule activators of SIRT1, such as SRT2104, and SIRT3, such as 2-acetyl-4-phenylquinoline (2-AQPC) and SZC-6 have been identified. In parallel, NAD<sup>+</sup> augmenting through supplementation of NAD<sup>+</sup> precursors such as nicotinamide riboside and nicotinamide mononucleotide has shown similar promising metabolic benefits in preclinical rodent models. Sirtuin-mediated lysine deacetylation represents a central mechanism regulating metabolic function and a promising target for therapeutic intervention in cardiometabolic disease.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- Europe PMC
- DOI
- 10.3390/ph19101557
- Canonical
- link ↗
- Fetched
- 2026-10-31 MST
Cite this
APA
K, T., & VW., D. (2026). Lysine Acetylation as a Regulatory Mechanism in Cardiometabolic Disease: A Focus on Sirtuins. <em>Pharmaceuticals (Basel, Switzerland)</em>. https://doi.org/10.3390/ph19101557
Vancouver
K T, VW. D. Lysine Acetylation as a Regulatory Mechanism in Cardiometabolic Disease: A Focus on Sirtuins. Pharmaceuticals (Basel, Switzerland). 2026. doi:10.3390/ph19101557.
BibTeX
@article{trivedi2026Lysine,
title = {Lysine Acetylation as a Regulatory Mechanism in Cardiometabolic Disease: A Focus on Sirtuins.},
author = {Trivedi K and Dolinsky VW.},
journal = {Pharmaceuticals (Basel, Switzerland)},
year = {2026},
doi = {10.3390/ph19101557},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Pharmaceuticals 2026
Open access · CC-BY
Lysine Acetylation as a Regulatory Mechanism in Cardiometabolic Disease: A Focus on Sirtuins
Journal of Obesity & Metabolic Syndrome 2023
Open access · CC-BY
Mitochondrial Quality Control: Its Role in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Current Obesity Reports 2022
Open access · CC-BY
Hepatocyte Mitochondrial Dynamics and Bioenergetics in Obesity-Related Non-Alcoholic Fatty Liver Disease
Frontiers in neurology 2026
Citation only
NAD<sup>+</sup> signaling in Parkinson's disease: molecular mechanisms and therapeutic perspectives.
Clinical and Translational Medicine 2016
Open access · CC-BY
Emerging therapeutic roles for NAD+ metabolism in mitochondrial and age‐related disorders
Frontiers in Physiology 2018
Open access · CC-BY